Karo Healthcare Acquisition: Karo Healthcare has confirmed the acquisition of a portfolio of skin health brands, including ACO, from Perrigo Company, following KKR's acquisition of Karo. The transaction, expected to close in Q1 2026, aims to enhance Karo's presence in the European consumer healthcare market.
Strategic Growth: This acquisition is seen as a significant step in Karo's strategy to become a multi-channel leader in consumer healthcare, providing a range of trusted, science-backed skincare brands and expanding its market reach, particularly in Northern Europe and Poland.
PRGO
$13.02+Infinity%1D
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 12.840
Low
23.00
Averages
27.50
High
32.00
Current: 12.840
Low
23.00
Averages
27.50
High
32.00
JPMorgan
Neutral
downgrade
$20 -> $18
2025-12-15
New
Reason
JPMorgan
Price Target
$20 -> $18
2025-12-15
New
downgrade
Neutral
Reason
JPMorgan lowered the firm's price target on Perrigo to $18 from $20 and keeps a Neutral rating on the shares. The firm updated the company's model.
Canaccord
Buy
downgrade
$40 -> $20
2025-11-06
Reason
Canaccord
Price Target
$40 -> $20
2025-11-06
downgrade
Buy
Reason
Canaccord lowered the firm's price target on Perrigo to $20 from $40 and keeps a Buy rating on the shares. The firm noted Q3 was a beat but sales were weak in light of OTC trends and lower nutrition sales due to velocities below expectations and lapping a period where infant formula benefited from selling into retailers due to the port strike last year.
JPMorgan
Overweight -> Neutral
downgrade
$32 -> $20
2025-11-06
Reason
JPMorgan
Price Target
$32 -> $20
2025-11-06
downgrade
Overweight -> Neutral
Reason
JPMorgan downgraded Perrigo to Neutral from Overweight with a price target of $20, down from $32, post the Q3 report. The firm sees increased uncertainty for the business in the near term and over the next 12 months. The recovery in Perrigo's infant formula business is slower than expected amid competitive pressure and its over-the-counter market trends are uncertain, the analyst tells investors in a research note. JPMorgan prefers to revisit shares when it gets more clarity on these dynamics.
Jefferies
Keith Devas
Hold
downgrade
$27 -> $23
2025-10-27
Reason
Jefferies
Keith Devas
Price Target
$27 -> $23
2025-10-27
downgrade
Hold
Reason
Jefferies analyst Keith Devas lowered the firm's price target on Perrigo to $23 from $27 and keeps a Hold rating on the shares. Macro headwinds continue to be felt more acutely in consumer health than other pockets of staples, says the analyst, who lowered targets and estimates across the firm's consumer health coverage into Q3 earnings reports from the group.
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
